Get the Stockscreener App
25.55
1.91%
0.48
Harrow Inc stock is traded at $25.55, with a volume of 546.86K.
It is up +1.91% in the last 24 hours and down -11.68% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$25.07
Open:
$24.85
24h Volume:
546.86K
Relative Volume:
1.14
Market Cap:
$828.60M
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-26.61
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
+6.50%
1M Performance:
-11.68%
6M Performance:
-49.51%
1Y Performance:
+155.50%
1-Day Range:
$24.09
$25.58
1-Week Range:
$22.83
$25.58
52-Week Range:
$10.04
$59.23
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
102 WOODMONT BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
25.55 | 828.60M | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
153.47 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.87 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
291.38 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic L - GuruFocus
Harrow (HROW) Partners with Nordic Pharma for Maxitrol Generic Launch - GuruFocus
Harrow and Nordic Pharma to launch generic version of Novartis' Maxitrol - Seeking Alpha
Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment - marketscreener.com
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) - Morningstar
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives Propel Success - GuruFocus
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients - Business Wire
Where Harrow Stands With AnalystsHarrow (NASDAQ:HROW) - Benzinga
B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener
H.C. Wainwright maintains $57 target on Harrow Health stock - Investing.com
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance
Harrow Health Reports Strong 2024 Financial Performance - TipRanks
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha
Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail
Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Harrow: Q4 Earnings Snapshot - The Advocate
Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire
Harrow Health (HROW) Surpasses Q4 Earnings and Revenue Expectati - GuruFocus
Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com
Harrow Inc (HROW) Shares Gap Down to $27.235 on Mar 26 - GuruFocus
Harrow sees shares increase following drug approval - Nashville Post
Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire
TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan
Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India
What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus
Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus
Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa
Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.
Harrow stock surges on preliminary Q4 numbers - Nashville Post
Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com
Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India
Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com
Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
| BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
| Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
29.64 |
5,000 |
148,200 |
145,000 |
| Opaleye Management Inc. | 10% Owner |
Feb 28 '25 |
Sale |
28.05 |
5,000 |
140,250 |
150,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 22 '25 |
Sale |
35.59 |
20,000 |
711,814 |
155,000 |
| SAHAREK JOHN P. | CEO of ImprimisRx |
Sep 11 '24 |
Option Exercise |
7.37 |
90,000 |
663,300 |
344,803 |
0.00%
1.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):